

Stefan Zeuzem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2799733/publications.pdf>

Version: 2024-02-01

67
papers

9,095
citations

201385

27
h-index

106150

65
g-index

67
all docs

67
docs citations

67
times ranked

8611
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
2	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
3	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.	13.9	752
4	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741
5	Retreatment of HCV with ABT-450/râ€“Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614.	13.9	536
6	Clinical Course of acuteâ€“onâ€“chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
7	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. <i>New England Journal of Medicine</i> , 2017, 376, 2134-2146.	13.9	467
8	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
9	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
10	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
11	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
12	Patterns of Resistance-Associated Substitutions in Patients Withâ€“Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	0.6	132
13	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012, 55, 749-758.	3.6	108
14	Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2018, 69, 1178-1187.	1.8	98
15	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	3.6	82
16	Resistance analysis in patients with genotype 1â€“6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. <i>Journal of Hepatology</i> , 2018, 68, 895-903.	1.8	82
17	Progress towards hepatitis C virus elimination in highâ€“income countries: An updated analysis. <i>Liver International</i> , 2021, 41, 456-463.	1.9	81
18	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , 2021, 75, 1346-1354.	1.8	69

#	ARTICLE	IF	CITATIONS
19	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. <i>Journal of Hepatology</i> , 2018, 69, 1221-1230.	1.8	50
20	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	3.0	50
21	Human colon organoids reveal distinct physiologic and oncogenic Wnt responses. <i>Journal of Experimental Medicine</i> , 2019, 216, 704-720.	4.2	49
22	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. <i>Gut</i> , 2020, 69, 1535-1536.	6.1	42
23	Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. <i>FEBS Letters</i> , 2000, 472, 129-132.	1.3	40
24	The recent outbreak of acute severe hepatitis in children of unknown origin – what is known so far. <i>Journal of Hepatology</i> , 2022, 77, 237-242.	1.8	37
25	Promoter Methylation of MLH1, PMS2, MSH2 and p16 Is a Phenomenon of Advanced-Stage HCCs. <i>PLoS ONE</i> , 2014, 9, e84453.	1.1	34
26	Î±-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2587-2594.	1.1	31
27	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31
28	Colonization with multidrug-resistant organisms is associated with increased mortality in liver transplant candidates. <i>PLoS ONE</i> , 2021, 16, e0245091.	1.1	29
29	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
30	A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. <i>Transplant International</i> , 2016, 29, 369-380.	0.8	26
31	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
32	Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00223.	1.3	22
33	Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e179-e187.	2.9	22
34	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , 2018, 35, 843-857.	1.3	17
35	Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0223613.	1.1	16
36	Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers. <i>Cancers</i> , 2021, 13, 2121.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	1.0	14
38	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	2.2	13
39	Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?. <i>Gut</i> , 2022, 71, 1036-1038.	6.1	13
40	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
41	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 α 3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
42	DNA mismatch repair activity of MutL \pm is regulated by CK2-dependent phosphorylation of MLH1 (S477). <i>Molecular Carcinogenesis</i> , 2018, 57, 1723-1734.	1.3	11
43	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 240-248.	1.4	11
44	Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648. <i>Molecular Carcinogenesis</i> , 2017, 56, 1816-1824.	1.3	10
45	Liver Transplantation in Acute-on-Chronic Liver Failure: Considerations for a Systematic Approach to Decision Making. <i>Visceral Medicine</i> , 2018, 34, 291-294.	0.5	10
46	Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis. <i>Frontiers in Immunology</i> , 2020, 11, 1447.	2.2	8
47	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	1.8	8
48	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. <i>Liver Transplantation</i> , 2020, 26, 1652-1657.	1.3	8
49	Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2409.	1.8	7
50	Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia. <i>Gut</i> , 2021, 70, 221-222.	6.1	7
51	Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2020, 26, 2097-2110.	1.4	7
52	Risk factors and outcomes associated with the carriage of tigecycline- and vancomycin-resistant. <i>Journal of Infection</i> , 2021, 82, 227-234.	1.7	6
53	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	6
54	Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". <i>Journal of Hepatology</i> , 2017, 67, 1350-1352.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis. <i>Cancers</i> , 2022, 14, 1641.	1.7	5
56	Overview of Commercial HBV Assay Systems. , 2004, 95, 3-14.		4
57	Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. <i>Ultraschall in Der Medizin</i> , 2020, , .	0.8	4
58	Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation. <i>PLoS ONE</i> , 2022, 17, e0263989.	1.1	4
59	Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, G1226-G1232.	1.6	3
60	PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure. <i>Journal of Hepatology</i> , 2019, 70, e111.	1.8	3
61	Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. <i>Gut Pathogens</i> , 2020, 12, 51.	1.6	3
62	Comparison of short-course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	3
63	Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , 2018, 34, 243-244.	0.5	2
64	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	1.9	2
65	Investigation of the Wilson gene ATP7B transcriptional start site and the effect of core promoter alterations. <i>Scientific Reports</i> , 2021, 11, 7674.	1.6	2
66	Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding. <i>PLoS ONE</i> , 2022, 17, e0268638.	1.1	2
67	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 2057.	1.0	1